Passage Bio (PASG)10% owner bought ~$241K
Lynx1 Capital Management LP, 10% owner at Passage Bio, bought ~$241K of Passage Bio shares.
- ~$241K
- Approx. value · 374K sh @ $0.6451
- 9.26M
- Holds after · shares reported
- Traded
- Dec 27, 2024
- Filed
- Dec 31, 2024
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Nov 25, 2024Insider10% owner purchased ~$147K of PASG shares in the open market
- Nov 26, 2024Insider10% owner purchased ~$118K of PASG shares in the open market
- Nov 27, 2024Insider10% owner purchased ~$20K of PASG shares in the open market
- Dec 4, 2024Insider10% owner sold ~$60K of PASG shares in the open market
- Dec 6, 2024Insider10% owner sold ~$17K of PASG shares in the open market
- Dec 9, 2024Insider10% owner sold ~$46K of PASG shares in the open market
- Dec 10, 2024Insider10% owner sold ~$6.4K of PASG shares in the open market
- Dec 11, 2024Insider10% owner sold ~$64 of PASG shares in the open market
- Dec 20, 2024Insider10% owner sold ~$138K of PASG shares in the open market
- Dec 27, 2024 · this disclosureInsider10% owner purchased ~$241K of PASG shares in the open market
What came next
- Jan 6, 2025Insider10% owner sold ~$15K of PASG shares in the open market
- Jan 7, 2025Insider10% owner sold ~$37K of PASG shares in the open market
- Jan 8, 2025Insider10% owner sold ~$51K of PASG shares in the open market
- Jan 10, 2025Insider10% owner sold ~$83K of PASG shares in the open market
- Jan 13, 2025Insider10% owner sold ~$12K of PASG shares in the open market
- Jan 14, 2025Insider10% owner sold ~$47K of PASG shares in the open market
- Feb 11, 2025InsiderCFO sold ~$1.7K of PASG shares in the open market
- Apr 15, 2025Insider10% owner sold ~$3.9K of PASG shares in the open market
- Apr 16, 2025Insider10% owner sold ~$20K of PASG shares in the open market
- Apr 17, 2025Insider10% owner sold ~$25K of PASG shares in the open market
- Apr 22, 2025Insider10% owner sold ~$27K of PASG shares in the open market
- Apr 23, 2025Insider10% owner sold ~$30K of PASG shares in the open market
- Apr 24, 2025Insider10% owner sold ~$22K of PASG shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Passage Bio
OQRO holds no insider, Congress, fund or contract record for Passage Bio dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PASG page.
Other recent filings by Lynx1 Capital Management LP, 10% owner
- SEC Form 4 at Passage Bio (PASG)Jun 30, 2026
- SEC Form 4 at Tscan Therapeutics (TCRX)Dec 23, 2025
- SEC Form 4 at Tscan Therapeutics (TCRX)Dec 23, 2025
- SEC Form 4 at Tscan Therapeutics (TCRX)Dec 23, 2025
- SEC Form 4 at Neuphoria Therapeutics (NEUP)Oct 24, 2025
The full history of Lynx1 Capital Management LP, 10% owner is on the profile page.
How this filing works
Other disclosures at Passage Bio
- SEC Form 4Jun 30, 2026
- SEC Form 4Jan 13, 2026
- SEC Form 4Jan 13, 2026
- SEC Form 4Sep 16, 2025
- SEC Form 4Sep 16, 2025
- SEC Form 4Sep 16, 2025
Everything OQRO holds on this company is on its PASG page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data